Letter to the editor of Heliyon re: determination of dimethylamine and nitrite in pharmaceuticals by ion chromatography to assess the likelihood of nitrosamine formation Heliyon. 2021; 77: e06179.


Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
Jun 2022
Historique:
received: 16 02 2022
revised: 09 03 2022
accepted: 26 05 2022
entrez: 23 6 2022
pubmed: 24 6 2022
medline: 24 6 2022
Statut: epublish

Résumé

Our letter to the editor of Heliyon outlines queries on the methodology and sample preparation used in article e06179, published in 2021. The nitrite measurements reported are higher than those observed in our experience. In the interest of reporting nitrite levels that are fully accurate, we would like to discuss the findings with the article authors.

Identifiants

pubmed: 35734570
doi: 10.1016/j.heliyon.2022.e09607
pii: S2405-8440(22)00895-7
pmc: PMC9207614
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e09607

Informations de copyright

© 2022 The Author(s).

Déclaration de conflit d'intérêts

The authors declare the following conflict of interest: The authors Joerg Schlingemann, Sebastian Hickert, Giorgio Blom, and Leonardo Allain are employed by companies that manufacture pharmaceuticals subject to regulations regarding maximum nitrosamine limits.

Références

Ultrason Sonochem. 2000 Jul;7(3):109-13
pubmed: 10909728
Heliyon. 2021 Feb 19;7(2):e06179
pubmed: 33665410
J Pharm Sci. 2022 Apr 29;:
pubmed: 35500671

Auteurs

Joerg Schlingemann (J)

Merck KGaA, Frankfurter Str. 250, Darmstadt, 64293, Germany.

Sebastian Hickert (S)

Merck KGaA, Frankfurter Str. 250, Darmstadt, 64293, Germany.

Giorgio Blom (G)

Chemical Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, UK.

Grace Kocks (G)

Lhasa Limited, Leeds, UK.

Leonardo Allain (L)

Analytical R&D, Merck & Co., Inc., Rahway, NJ, 07065, USA.

Classifications MeSH